<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08274</article-id><article-id pub-id-type="doi">10.7554/eLife.08274</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Prefrontal dopamine regulates fear reinstatement through the downregulation of extinction circuits</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-33081"><name><surname>Hitora-Imamura</surname><given-names>Natsuko</given-names></name><aff><institution content-type="dept">Department of Pharmacology, Graduate School of Pharmaceutical Sciences</institution>, <institution>Hokkaido University</institution>, <addr-line><named-content content-type="city">Sapporo</named-content></addr-line>, <country>Japan</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33082"><name><surname>Miura</surname><given-names>Yuki</given-names></name><aff><institution content-type="dept">Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences</institution>, <institution>University of Tokyo</institution>, <addr-line><named-content content-type="city">Tokyo</named-content></addr-line>, <country>Japan</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33083"><name><surname>Teshirogi</surname><given-names>Chie</given-names></name><aff><institution content-type="dept">Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences</institution>, <institution>University of Tokyo</institution>, <addr-line><named-content content-type="city">Tokyo</named-content></addr-line>, <country>Japan</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-17867"><name><surname>Ikegaya</surname><given-names>Yuji</given-names></name><aff><institution content-type="dept">Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences</institution>, <institution>University of Tokyo</institution>, <addr-line><named-content content-type="city">Tokyo</named-content></addr-line>, <country>Japan</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33088"><name><surname>Matsuki</surname><given-names>Norio</given-names></name><aff><institution content-type="dept">Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences</institution>, <institution>University of Tokyo</institution>, <addr-line><named-content content-type="city">Tokyo</named-content></addr-line>, <country>Japan</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-21118"><name><surname>Nomura</surname><given-names>Hiroshi</given-names></name><aff><institution content-type="dept">Department of Psychiatry</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country><email>h-nomu@umin.ac.jp</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-16672"><name><surname>Bartos</surname><given-names>Marlene</given-names></name><role>Reviewing editor</role><aff><institution>Albert-Ludwigs-Universität Freiburg</institution>, <country>Germany</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>07</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e08274</elocation-id><supplementary-material><ext-link xlink:href="elife-08274-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>23</day><month>04</month><year>2015</year></date><date date-type="accepted"><day>29</day><month>07</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Hitora-Imamura et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Hitora-Imamura et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Prevention of relapses is a major challenge in treating anxiety disorders. Fear reinstatement can cause relapse in spite of successful fear reduction through extinction-based exposure therapy. By utilising a contextual fear-conditioning task in mice, we found that reinstatement was accompanied by decreased c-Fos expression in the infralimbic cortex (IL) with reduction of synaptic input and enhanced c-Fos expression in the medial subdivision of the central nucleus of the amygdala (CeM). Moreover, we found that IL dopamine plays a key role in reinstatement. A reinstatement-inducing reminder shock induced c-Fos expression in the IL-projecting dopaminergic neurons in the ventral tegmental area, and the blocking of IL D1 signalling prevented reduction of synaptic input, CeM c-Fos expression and fear reinstatement. These findings demonstrate that a dopamine-dependent inactivation of extinction circuits underlies fear reinstatement and may explain the comorbidity of substance use disorders and anxiety disorders.</p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>reinstatement</kwd><kwd>infralimbic cortex</kwd><kwd>dopamine</kwd><kwd>fear conditioning</kwd><kwd>fear extinction</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experiments were approved by the animal experiment ethics committee at The University of Tokyo (approval number 24-10) and were in accordance with The University of Tokyo guidelines for the care and use of laboratory animals. All surgery was performed under xylazine and pentobarbital anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></back></article>